Spectral Medical Inc. Files Base Shelf Prospectus
TORONTO – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company, is on an exciting path to revolutionize treatment for sepsis and septic shock. Recently, the Company announced a significant development as it filed a final short form base shelf prospectus (the “Base Shelf Prospectus”) with the securities regulatory authorities in Canada, noting the Effective Date of the filing.
Understanding the Base Shelf Prospectus
This new Base Shelf Prospectus permits Spectral to qualify for the distribution of up to $100 million in common shares, debt securities, subscription receipts, warrants, and units, or any combination thereof. This opportunity exists over a 25-month period, beginning from the Effective Date. The specific details of any offering will be outlined in a prospectus supplement filed during each offering phase, ensuring regulatory compliance.
Regulatory Compliance and Recent Updates
In line with good governance, Spectral has also revised its Annual Information Form (“AIF”) for the previous fiscal year, responding to inquiries from the Ontario Securities Commission. This revision aims to ensure transparency regarding a director's previous involvement in a corporation that faced bankruptcy proceedings, alongside incorporating crucial updates related to the Tigris clinical trial results.
Access to Company Data
For those interested in reviewing the Base Shelf Prospectus and the revised AIF, both documents can be accessed under Spectral's company profile on SEDAR+.
About Spectral and its Innovations
Focused on transforming the medical landscape, Spectral is a Phase 3 company working diligently toward obtaining U.S. FDA approval for its innovative treatment, Toraymyxin™ (“PMX”). This unique therapeutic hemoperfusion device works by removing endotoxins that can lead to sepsis, backed by the Company’s FDA-cleared Endotoxin Activity Assay (EAA™), a test designed for endotoxin detection in the bloodstream.
Global Impact of PMX
PMX is already making waves internationally, having gained approval for therapeutic use in regions such as Japan and Europe, with its licensing secured through Health Canada. To date, over 360,000 PMX units have been distributed globally, reflecting strong market demand and successful outcomes. The U.S. FDA has also acknowledged PMX’s potential by granting Breakthrough Device Designation for the treatment of endotoxic septic shock, underscoring its importance in critical care.
The Tigris Trial and Its Importance
The Tigris Trial represents a pivotal study for PMX, designed to confirm its efficacy compared to standard care alone. Encompassing 150 patients, this 2:1 randomized trial utilizes Bayesian statistics to achieve accurate results. Endotoxic septic shock presents severe challenges within sepsis cases, highlighting the need for effective treatment options, and this trial aims to validate PMX’s effectiveness in clinical settings.
Future Directions and Commitment to Commitment to Patients
Spectral Medical Inc. continues to exemplify its dedication to scientific advancement and patient care. With a clear focus on innovation and improving treatment opportunities for patients facing severe health challenges, the Company envisions a future where sepsis management is markedly improved.
For more information about Spectral and its initiatives, visit their official website.
Frequently Asked Questions
What is the base shelf prospectus filed by Spectral Medical Inc.?
The base shelf prospectus allows Spectral to raise up to $100 million for various types of securities over a specified period.
How does PMX help in the treatment of sepsis?
PMX is a therapeutic device that removes harmful endotoxins from the bloodstream, which can cause sepsis, thereby improving patient outcomes.
What recent updates have been made to the Annual Information Form?
The AIF was revised to address a director's previous role in bankruptcy and to include updates on the Tigris clinical trial results.
How many units of PMX have been sold globally?
Over 360,000 units of PMX have been sold worldwide, reflecting strong demand for its therapeutic use.
What is the significance of the Tigris Trial?
The Tigris Trial aims to confirm the efficacy of PMX compared to standard care alone, using Bayesian statistics to ensure robust results.
